Table 1

Baseline characteristics of BEVORDEX treatment groups that were followed

DEX-implant
(46 eyes)
Bevacizumab
(42 eyes)
P value
Mean follow-up, days (CI)1366 (1215 to 1516)1488 (1364 to 1611)0.2
Baseline BCVA, letters (SD)55.5 (12.5)56.3 (11.9)0.75
Baseline CMT, ┬Ám (SD)474.3 (95.9)503 (140.9)0.38
Number of eyes that had 5-year follow-up26260.61
Baseline phakic eyes30320.81
Baseline NPDR31320.58
  • BCVA, best corrected visual acuity; CMT, central macular thickness; DEX, dexamethasone; NPDR, non-proliferative diabetic retinopathy.